DOCSLIB.ORG

(12) United States Patent (10) Patent N0.: US 8,975,245 B2 Goodchild Et A]

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent N0.: US 8,975,245 B2 Goodchild Et A] USOO8975245B2 (12) United States Patent (10) Patent N0.: US 8,975,245 B2 Goodchild et a]. (45) Date of Patent: *hlar.10,2015 (54) ANAESTHETIC FORMULATION (56) References Cited (71) Applicant: DraWbridge Pharmaceuticals Pty Ltd, U.S. PATENT DOCUMENTS Southbank (AU) 2003/0055023 A1 3/2003 Rajewski et a1. 2003/0073665 A1 4/2003 Thompson et al. (72) Inventors: Juliet Marguerite Goodchild, Malvem (AU); Colin Stanley Goodchild, FOREIGN PATENT DOCUMENTS Malvern (AU); Benjamin James Boyd, Warrandyte (AU) EP 0399716 Bl 1/1994 W0 WO 93/17711 Al 9/1993 (73) Assignee: DraWbridge Pharmaceuticals Pty Ltd, W0 WO 01/70234 Al 9/2001 Southbank, Victoria (AU) W0 WO 2004/039426 A2 5/2004 OTHER PUBLICATIONS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 Brewster, M.E. et a1. 1989 “Development of a Non-Surfactant For U.S.C. 154(b) by 0 days. mulation for Alfaxalone Through the Use of Chemically-Modi?ed This patent is subject to a terminal dis Cyclodextrins” Journal ofParenteral Science & Technology 43: 262 claimer. 265. Brewster, M.E. et al. 1995 “Preparation, Characterization, and Anes (21) Appl. N0.: 14/069,751 thetic Properties of 2-hydroxypr0pyl-[5-cyclodextrin Complexes of Pregnenolone in Rat and Mouse” Journal of Pharmaceutical Sci (22) Filed: Nov. 1, 2013 ences 84: 1154-1159. Chisari, M. et al. 2009 “The In?uence of Neuroactive Steroid (65) Prior Publication Data Lipophilicity 0n GABAA Receptor Modulation: Evidence for a Low Af?nity Interaction” J Neurophysiol 102: 1254-1264. US 2014/0066417 A1 Mar. 6, 2014 Egan, T.D. et al. 2003 “The Pharmacokinetics and Pharmacodynam ics of Propofol in a Modi?ed Cyclodextrin Formulation (Captisol®) Related US. Application Data Versus Propofol in a Lipid Formulation (Diprivan®): An (63) Continuation of application No. 13/574,201, ?led as Electroencephalographic and Hemodynamic Study in a Porcine application No. PCT/AU2011/000050 on Jan. 19, Model” Anesth Analg 97:72-79. Ramsay, et al. 1974 “Controlled Sedation with Alphaxalone 2011, now Pat. No. 8,697,678. Alphadolone” British Medical Journal 2: 656-659. (60) Provisional application No. 61/297,249, ?led on Jan. Sneyd, J .R. et al. 1997 “Computer-controlled infusion of ORG 21, 2010, provisional application No. 61/385,318, 21465, a water soluble steroid i.v. anaesthetic agent, into human ?led on Sep. 22, 2010. volunteers” British J Anaethesia 79: 433-439. Supplemental European Search Report, in corresponding European (51) Int. Cl. Application No. EP 11 73 4245, dated Jan. 17,2014. A61K 31/56 (2006.01) A61K 47/40 (2006.01) Primary Examiner * Paul Zarek A61K 31/57 (2006.01) (74) Attorney, Agent, or Firm * Knobbe, Martens Olson & A61K 47/48 (2006.01) Bear, LLP B82Y5/00 (2011.01) A61K 31/5 73 (2006.01) (57) ABSTRACT (52) US. Cl. The present invention relates generally to the ?eld of drug CPC ............... .. A61K47/40 (2013.01); A61K31/56 delivery systems for neuroactive steroid anaesthetic agents. (2013.01); A61K31/57 (2013.01); A61K More particularly, anaesthetic and sedative formulations are 47/48969 (2013.01); B82Y5/00 (2013.01); provided in the form of host/guest preparations comprising A61K31/573 (2013.01) one or more neuroactive steroid anaesthetics and a cyclodex USPC ........................................................ .. 514/178 trin. Particular cyclodextrins contemplated include sulfoalkyl (58) Field of Classi?cation Search ether cyclodextrins and modi?ed forms thereof. CPC ..................... .. A61K47/48969; A61K 31/573 See application ?le for complete search history. 9 Claims, 9 Drawing Sheets US. Patent Mar. 10, 2015 Sheet 1 0f9 US 8,975,245 B2 Prepafei Habit mgresséian far 1653 rig?ting; m?'ekx and wit gith Wrightmgreiiex mean w ~ -~~ righ thigreaiiex {I} . : m mi; piimi: s'uésan '1 19 1 {50 Figure 1a Propofei: Rota we! Tes?'ime Respnnse Curves {ime after iv ink'ctisn iminuies' rotaersemndstimerun Figure 1b US. Patent Mar. 10, 2015 Sheet 2 0f9 US 8,975,245 B2 .Attha$§n® wai’t regre?sian'far iiosg righting m?ex and v’tsaii pinch respnmea. Figure 1c Aithesin: Rotamd Tes?'ime Respcmse Curves time after iv injae?an {minute‘s} 128 I ‘ 23.3‘ ‘ ' 3.5' ' ' 5% Si}>17 333 18.9 mtamdtimeseccmdsrun Figure 1d US. Patent Mar. 10, 2015 Sheet 3 0f9 US 8,975,245 B2 Phaxanw Prabit regressian far tass rifght'ing {effex and taii piimk reswrzses rm: righting reiiax “wan “55 g “ WM ~' righting {€¥¥€>¢1 1f} :5 a>22 'W tad‘ . mush._ mean. , i in W}. pimh u dng ii-QEQ- 12mg} kg iv} Wm» fierims Figure 1e iPhaxanCD: Rota red Tes?ime RESPQHSE Curves time after iv iniectizm (minute's? z? 5 2;? 3,5 51:; 8,0 13,0 3&2 S ? ° 3 {T ‘i';g ~ ~ ~ ~ ~ ~ ~ - ' - ' - ' - ' - ' - ' - ' - ' - ' - ' "1 1 a 40 .................. .: t *f ~ ‘ ‘J 2 A .ép; Q . Figure 1f US. Patent Mar. 10, 2015 Sheet 4 0f9 US 8,975,245 B2 Letihaiity Pint: yaw data dam {mgfkg iv} Figure 2 Qiithesin Fmbit 9E0? far ‘mth‘aiity 3. a, gambitvaiua v1p means dew: tiese {mgfkg iv} Figure 3 US. Patent Mar. 10, 2015 Sheet 5 0f9 US 8,975,245 B2 sieep time {minuteg mean, sem, n = 5} after repeated dases of PhaxanCE} {Ma?a} siieepingtimez-{minutes} L11w04@- 'i 3 3- 11 .5 8 7 19 Figure 4 Pravgnamimnew: Rightng Refiax Yizme Rewamse {Zwves deathai'amawhaa-ia Figure 5 US. Patent Mar. 10, 2015 Sheet 6 0f9 US 8,975,245 B2 Pregnamlanew: Ta? Pimi?ime Respnnsa Curvea deptha?sihesiasnags time ?ier iv iniesticm iminutes} Figure 6 Pregnanoianew: Rntamd Tes?ime Respanse Curves time a?er iv injectinn {minutes} 63 3.5 51'! 3,0 121% 3313 36:3 3 0 ' » -. L ~ : ~ -. 2 ~ : ~ y 2' ~ : ~ . .l - : ' a ma :6? ziegzth?ames-them $9 .. ........................................................................................................................................................................... g§ .................... “?lm ma?fka'? Figure 7 US. Patent Mar. 10, 2015 Sheet 7 0f9 US 8,975,245 B2 Alphadaianem: Rightirs'g Re?ex Yi'ma Rasgmnse Cu was deptha?si?e-siama {3.5 1.5 2.5 if» (11) iiiil‘iiiiliii} time aiter iv Mamas iminutasi Figure 8 Aiphadolsnem: Tai? Pincm'ima Respan'se {Zurvas £15 1.5 335 3L5 119 ?? 39.0 14,9 183’} time whet is? injse'atian iminuies} Figure 9 US. Patent Mar. 10, 2015 Sheet 8 0f9 US 8,975,245 B2 Aipiaadamnaw: Ratamd Tesffime Respanse turves tima a?er iv injactien Minutes; 13.51} ' W: 21-1: damho§anaasahes-ia % Changa in mean systmic hkmd pmssure time after iv in§ecti<m iminutm) i) .‘1 '18 115 10 ermmioi m5 w?-Mfakhesin changeinpressure --- F‘i'm'x anCD Figure 11 US. Patent Mar. 10, 2015 Sheet 9 0f9 US 8,975,245 B2 % Qhange in mean diastotilc bicmd pressure time after iv inietrtiien {minut?s} £3 5 eihangeinpressure $6} Figure 12 US 8,975,245 B2 1 2 ANAESTHETIC FORMULATION Currently, a lipid formulation of di-isopropyl phenol (pro pofol) is the most highly used anaesthetic agent. Propofol, This application is a continuation of US. application Ser. however, can be contraindicated in certain at risk patients due No. 13/574,201, ?ledAug. 30, 2012, now US. Pat. No. 8,697, to its lowering effect on blood pressure, the effect it has on 678, which is the US. national phase of International Appli reducing cardiac output and it can adversely affect respiratory cation No. PCT/AU11/00050, ?led Jan. 19, 2011, which control. In particular, propofol is formulated in a lipid emul claims priority from US. Provisional Patent Application No. sion which can support microbial growth if contaminated. 61/297,249, ?led on 21 Jan. 2010, entitled “Anaesthetic for The formulation cannot, in fact, be sterilized. There have been mulation” AND U.S. Provisional Patent Application No. instances where microbially contaminated propofol formula 61/385,318 ?led on 22 Sep. 2010, entitled “Anaesthetic for tions have resulted in patients becoming infected. One other mulation,” the entire contents of which, are incorporated issue with the current propofol formulation is the pain herein by reference. induced following or during intravenous injection. Attempts to re-formulate in a water-based preparation have led to FIELD increased injection pain. Propofol also can lead to cardiovas The present invention relates generally to the ?eld of drug cular and respiratory depression and has a low therapeutic delivery systems for neuroactive steroid anaesthetic agents. index of 5, i.e. only 5 times the normal anaesthetic dose can More particularly, anaesthetic and sedative compositions are lead to death. Furthermore, the anaesthetic is incompatible provided in the form of host/ guest preparations comprising with plastic storage containers and plastic syringes which one or more neuroactive steroid anaesthetics and a cyclodex 20 complicates syringe delivery equipment which is frequently trin or a modi?ed form thereof. in standard use for intravenous anaesthesia and sedation. The drug can also cause hyperlipidaemia and can induce toxicity BACKGROUND when used in a larger dose by infusion. This is particularly problematic in the intensive care setting. Bibliographic details of references provided in the subject 25 A neuroactive steroid anaesthetic has the potential for speci?cation are listed at the end of the speci?cation. being more ef?cacious with fewer side effects than propofol. Reference to any prior art is not, and should not be taken as There is a need, therefore, to develop a suitable formulation an acknowledgment or any form of suggestion that this prior to enable the use of a neuroactive steroid anaesthetic agent in art forms part of the common general knowledge in any subjects. country. 30 Drug delivery systems aim to provide the required amount SUMMARY of drug systemically or to a targeted site for a time and under conditions suf?cient to have the desired effect.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Veterinary Anaesthesia (Tenth Edition)
    W. B. Saunders An imprint of Harcourt Publishers Limited © Harcourt Publishers Limited 2001 is a registered trademark of Harcourt Publishers Limited The right of L.W. Hall, K.W. Clarke and C.M. Trim to be identified as the authors of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without either the prior permission of the publishers (Harcourt Publishers Limited, Harcourt Place, 32 Jamestown Road, London NW1 7BY), or a licence permitting restricted copying in the United Kingdom issued by the Copyright Licensing Agency Limited, 90 Tottenham Court Road, London W1P 0LP. First edition published in 1941 by J.G. Wright Second edition 1947 (J.G. Wright) Third edition 1948 (J.G. Wright) Fourth edition 1957 (J.G. Wright) Fifth edition 1961 (J.G. Wright and L.W. Hall) Sixth edition 1966 (L.W. Hall) Seventh edition 1971 (L.W. Hall), reprinted 1974 and 1976 Eighth edition 1983 (L.W. Hall and K.W. Clarke), reprinted 1985 and 1989 Ninth edition 1991 (L.W. Hall and K.W. Clarke) ISBN 0 7020 2035 4 Cataloguing in Publication Data: Catalogue records for this book are available from the British Library and the US Library of Congress. Note: Medical knowledge is constantly changing. As new information becomes available, changes in treatment, procedures, equipment and the use of drugs become necessary. The authors and the publishers have taken care to ensure that the information given in this text is accurate and up to date.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Proceedings of the Anaesthetic Research Society Glasgow Meeting July 7, 1979
    Br.J. Anaesth. (1979), 51-, 989P PROCEEDINGS OF THE ANAESTHETIC RESEARCH SOCIETY GLASGOW MEETING JULY 7, 1979 EFFECT OF KETAMINE ON TRANSMISSION a 50% depression in the response to carbachol 5.46 x 10~6 1 5 IN SYMPATHETIC GANGLIA mol litre" was determined (IC50 ketamine = 8.5 x 10" 1 mol litre" , r = 0.83). Downloaded from https://academic.oup.com/bja/article/51/10/989/304330 by guest on 29 September 2021 V. MAHMOODI, A. J. BYRNE, T. E. J. HEALY AND In the concentrations used ketamine has been shown to S. Z. HUSSAIN interfere with the sympathetic final common pathway but Department of Surgery {Anaesthesia), Queen's Medical the results do not preclude a central effect at lower con- Centre, University Hospital, Clifton Boulevard, centrations. Nottingham ACKNOWLEDGEMENT An increase in arterial pressure following the injection of We gratefully acknowledge financial support from Parke ketamine is well documented and has been explained by Davis and Co. both central (Ivankovich et al., 1974) and peripheral actions (Nedergaard, 1973). The sympathetic division of REFERENCES the autonomic nervous system is the link between central Hukovic, S. (1961). Br. J. Pharmacol, 16, 188. and peripheral mechanisms for increasing arterial pressure. Ivankovich, A. D., Miletich, D. J., Reimann, C, Albrecht, It was therefore decided to investigate the effects of keta- R. F., and Zahed, B. (1974). Anesth. Analg. {Cleve.), 53, mine on this final common pathway. 924. The hypogastric nerve, hypogastric plexus and vas Nedergaard, O. A. (1973). Eur. J. Pharmacol, 23, 153. deferens of adult guineapigs were dissected (Hukovic, 1961) and mounted in Krebs' solution bubbled with oxygen 95% and carbon dioxide 5% at 32 °C.
    [Show full text]
  • Lääkeaineiden Yleisnimet (INN-Nimet) 21.6.2021
    Lääkealan turvallisuus- ja kehittämiskeskus Säkerhets- och utvecklingscentret för läkemedelsområdet Finnish Medicines Agency Lääkeaineiden yleisnimet (INN-nimet) 21.6.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Abstract/Summary Development Targets in Anaesthetic
    University of Plymouth PEARL https://pearl.plymouth.ac.uk Faculty of Health: Medicine, Dentistry and Human Sciences Peninsula Medical School 2017-12-01 Thiopental to desflurane - an anaesthetic journey. Where are we going next? Sneyd, J http://hdl.handle.net/10026.1/9849 10.1093/bja/aex328 British Journal of Anaesthesia Oxford University Press (OUP) All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author. Thiopental to desflurane - an anaesthetic journey. Where are we going next? Abstract/summary Development targets in anaesthetic pharmacology have evolved from minimising harm caused by unwanted effects through an era in which rapid onset and offset of drug effect were prioritised. Today’s anaesthetists have access to a library of effective drugs whose characteristics offer controllable hypnosis, analgesia and paralysis with manageable off-target effects. The availability of these agents at generic prices inhibits commercial interest and this is reflected in the limited number of current anaesthetic drug development projects. Recently, questions around neonatal neurotoxicity, delirium and post-operative cognitive dysfunction have stimulated research to characterise these phenomena and explain them in mechanistic terms. Emergent basic science from these enquiries together with exploration of possible effects of anaesthetic drug choice on patient outcomes from cancer surgery may yield new targets for drug discovery. The past 40 years have seen extraordinary developments in anaesthetic pharmacology culminating in a limited but versatile set of hypnotics, analgesics and muscle relaxants adaptable to every clinical situation.
    [Show full text]